120 related articles for article (PubMed ID: 24586077)
1. Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction.
Elsoueidi R; Craig J; Mourad H; Richa EM
J Natl Compr Canc Netw; 2014 Feb; 12(2):155-60. PubMed ID: 24586077
[TBL] [Abstract][Full Text] [Related]
2. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
3. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Bokemeyer C; Bondarenko I; Makhson A; Hartmann JT; Aparicio J; de Braud F; Donea S; Ludwig H; Schuch G; Stroh C; Loos AH; Zubel A; Koralewski P
J Clin Oncol; 2009 Feb; 27(5):663-71. PubMed ID: 19114683
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
[TBL] [Abstract][Full Text] [Related]
5. FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases.
Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1205-8. PubMed ID: 21772113
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
8. [Cetuximab in association with an oxaliplatin-based chemotherapy as first-line treatment of metastatic colorectal cancer.].
Petrelli F; Ghidini A; Zaniboni A
Recenti Prog Med; 2017 Mar; 108(3):128-135. PubMed ID: 28398406
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
10. Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma.
Tural D; Akar E; Öztürk MA; Yıldız Ö; Turna H; Serdengeçti S
J Cancer Res Ther; 2014; 10(3):745-8. PubMed ID: 25313774
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
14. Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
Roderburg C; do O N; Fuchs R; Bubenzer J; Spannbauer M; Luedde T; Trautwein C; Tischendorf JJ
Clin Colorectal Cancer; 2011 Mar; 10(1):E6-9. PubMed ID: 21609928
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Tabernero J; Van Cutsem E; Díaz-Rubio E; Cervantes A; Humblet Y; André T; Van Laethem JL; Soulié P; Casado E; Verslype C; Valera JS; Tortora G; Ciardiello F; Kisker O; de Gramont A
J Clin Oncol; 2007 Nov; 25(33):5225-32. PubMed ID: 18024868
[TBL] [Abstract][Full Text] [Related]
16. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
18. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
19. Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Chan E; Kwak EL; Hwang J; Heiskala M; de La Bourdonnaye G; Mita M
Cancer Chemother Pharmacol; 2015 Apr; 75(4):701-9. PubMed ID: 25627002
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
Park SH; Sung JY; Han SH; Baek JH; Oh JH; Bang SM; Cho EK; Shin DB; Lee JH
Jpn J Clin Oncol; 2005 Sep; 35(9):531-5. PubMed ID: 16027146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
